I agree it would have been better if they had a representative there--
Note the Press was barred from the meeting--IMHO the best hope
would be for Current Board to find Buyer for the company--
Not impossible but not likely near term.
Hopefully Himesh and the Synacor team can gain traction
on a number of fronts and in next year have a company potentially
worth 1 1/2 to 2 X Revenues---Even $3.50 a year from now
would represent a good % return from current $2.36 price--
Just received encrypted message from some chap named Downtown Brown,
ostensibly from some organization called International Message Board Association--
Not sure that I decoded this correctly but I think it reads
"A lot of water over the dam"---"Give this a little rest"------"Suggest 24 hour moratorium
on the posting of any new messages"---
Can't verify authenticity---just reporting
After a careful review of all the posts on this thread IMHO
Today's news is neither "underwhelming", nor is Today's news "overwhelming"
My vote is to put this thread--to bed and move onward (and upward).
Yes--- Siga management & Board of Directors must now think about the words of Sir Walter Scott:
"Oh what a tangled web we weave,
When first we practise to deceive"
PS.---that's the way practice was spelled at the time--with an s instead of c
With stock at $8---approximately 14% since January--
Actually approximately 56% off on an annualized basis
(but that's probably a little overcritical)---To be fair,
anyone that followed her advice, sold at $7 and found something else to
buy with the proceeds would have come out all right---nevertheless
a substantial institutional investor (who did not have to make an either/or decision, and
could handle just holding ARWR) ---assuming 1,000,000 shares sold at $7 would have
not realized the $1,000,000 gain (still only a hypothetical paper gain at this point)
had they acted on Alithea's $7 price target---
Just keeping score--
rod ---There may be other places more "crooked"---
Hamburg now gone as of end of March ---Ostroff Acting Director
In 2014 my understanding 41 new drugs approved??---37% orphan drugs??
Several other existing drugs with different dosages and protocals also approved
To state the obvious--- It appears to me that not easy to get a new drug approved by FDA
and into commercial production--there must be hundreds of
biotech companies + big pharma working on thousands of drugs----
My understanding is that one is specific and one is non-specific---unfortunately I do
now know which one is which---Bill Clinton would probably say that it depends
specifically on the meaning of specific. I hope this helps---
Although I would like to think, and actually do think, that I have an
OWNERSHIP POSITION in a great company---a feeling that I am sure is shared by many on this Board--
On a given day, week or month etc.with all the volatility and the frenetic trading activity
by high frequency traders, hedge funds, momentum players it sometimes feels that
what I own is a number on the computer screen---
Ultimately, value will prevail IMHO
Please do not take this personally, but feel compelled to
advise you that you have violated an important Maxim
as related to the overall market, or to an individual stock:
"When you give a number, never give a date"
"When you give a date, never give a number"
Hope this helps
With the usual caveat that there are many risks involved (see SEC filings, and as
also highlighted in other threads on this MB) my own guess re ARC-ATT:
Assume 15,000 patients @ $80,000 = $1,200,000 (potential in 2018??)
Assume investor valuation methodolgy develops into a "Multiple of Revenue" model
Then assume (potenntially in 2018??) 6 X Revenues = $7,200,000,000 potential market cap
Assume 80,000,000 shares outstanding (hopefully conservative) but
company will be burning cash at rate of at least $20,000,000 quarterly
(perhaps even greater rate) Although sufficient cash currently, IMHO
management will not want to see their cash "war chest" below $100,000,000.
Also, They have issued new stock to Novartis in the patent deal and
there are, I am quite sure latent options involving stock strike prices
"not in the money" so adjusted shares outstanding are probably approximately
60,000,000 right now--
Although others may vehemently disagree, IMHO best to be conservative and figure 80,000,000 - 100,000,000 shares outstanding in 2018----It is possible that some partner deals will come along re DPC
and substantial funding for ARWR will come along to eliminate or reduce the need
for stock issuance.
In any event assuming $1,200,000,000 in revenues from ARC-ATT in 2018??
divided by even 100,000,000 shares outstanding at that time gets us to
$72 per share ---an approximate 10 Bagger!---Just my guesstimate ---and
alll of this just from ARC-ATT
Once again your hard work on this stock which you share is most appreciated.
I agree with rc
Although PSEC near term could bounce (along with most BDC's),
based on theory that today's March job report could delay increase
in short term rates---
IMHO MAIN management seems considerably more "shareholder friendly" and over long term has potential to achieve 7 - 9%
annualized rate of return (dividends +gradual appreciation)---
Would suggest careful reading of January Investor
presentation in the Investor section of MAIN Website which is detailed and really quite excellent source of information--
IMHO much more going on here than just a "dead cat bounce"---
Although many risks (see SEC filings) if we get FDA approval for
new protocol in next 30 - 60 days stock will respond big time--
IMHO a decent chance to reach double digits by year end
(assuming no glitches with FDA near term)---
Currently am thinking in terms of $12 price target by year end 2015---
an annualized rate of return of 80% from current $7.50 level--
Excellent call on HALO!